Quanterix Presenting at Canaccord Genuity 44th Annual Growth Conference
Quanterix (NASDAQ: QTRX), a company specializing in ultra-sensitive biomarker detection, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. CEO Masoud Toloue and CFO Vandana Sriram will engage in a fireside chat on August 13, 2024, at 3:00 p.m. ET. The presentation will be accessible virtually, with registration available through a provided link. Following the conference, the presentation will be made available on Quanterix's website. This event offers an opportunity for investors and interested parties to gain insights into Quanterix's operations and future prospects in the field of scientific discovery through biomarker detection.
Quanterix (NASDAQ: QTRX), un'azienda specializzata nella rilevazione di biomarker ultra-sensibili, ha annunciato la sua partecipazione al 44° Annual Growth Conference di Canaccord Genuity. Il CEO Masoud Toloue e il CFO Vandana Sriram parteciperanno a una conversazione informale il 13 agosto 2024, alle 15:00 ET. La presentazione sarà accessibile virtualmente, con registrazione disponibile tramite un link fornito. Dopo la conferenza, la presentazione sarà resa disponibile sul sito web di Quanterix. Questo evento offre un'opportunità per investitori e parti interessate di ottenere informazioni sulle operazioni di Quanterix e sulle prospettive future nel campo della scoperta scientifica attraverso la rilevazione di biomarker.
Quanterix (NASDAQ: QTRX), una empresa especializada en la detección de biomarcadores ultra-sensibles, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El CEO Masoud Toloue y la CFO Vandana Sriram participarán en un chat informal el 13 de agosto de 2024, a las 3:00 p.m. ET. La presentación será accesible de forma virtual, con registro disponible a través de un enlace proporcionado. Tras la conferencia, la presentación estará disponible en el sitio web de Quanterix. Este evento ofrece una oportunidad para que los inversores y partes interesadas obtengan información sobre las operaciones de Quanterix y las perspectivas futuras en el campo del descubrimiento científico a través de la detección de biomarcadores.
Quanterix (NASDAQ: QTRX), 초고감도 바이오마커 탐지 전문 기업이 Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. CEO Masoud Toloue와 CFO Vandana Sriram은 2024년 8월 13일 오후 3시 ET에 간담회에 참여할 예정입니다. 발표는 가상으로 진행되며, 제공된 링크를 통해 등록할 수 있습니다. 컨퍼런스 이후 발표 내용은 Quanterix 웹사이트에서 사용할 수 있습니다. 이 이벤트는 투자자와 이해관계자가 Quanterix의 운영 및 바이오마커 탐지를 통한 과학적 발견 분야에서의 미래 전망에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
Quanterix (NASDAQ: QTRX), une entreprise spécialisée dans la détection de biomarqueurs ultra-sensibles, a annoncé sa participation à la 44ème Conférence Annuelle sur la Croissance de Canaccord Genuity. Le PDG Masoud Toloue et la CFO Vandana Sriram participeront à une discussion informelle le 13 août 2024 à 15h00 ET. La présentation sera accessible virtuellement, avec une inscription disponible via un lien fourni. Après la conférence, la présentation sera mise à disposition sur le site web de Quanterix. Cet événement offre aux investisseurs et aux parties intéressées l'opportunité d'obtenir des informations sur les opérations de Quanterix et ses perspectives d'avenir dans le domaine de la découverte scientifique grâce à la détection de biomarqueurs.
Quanterix (NASDAQ: QTRX), ein Unternehmen, das auf die ultra-sensible Detektion von Biomarkern spezialisiert ist, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity angekündigt. CEO Masoud Toloue und CFO Vandana Sriram werden am 13. August 2024, um 15:00 Uhr ET an einem informellen Gespräch teilnehmen. Die Präsentation wird virtuell zugänglich sein, mit einer Registrierungsoption über einen bereitgestellten Link. Nach der Konferenz wird die Präsentation auf der Website von Quanterix verfügbar sein. Diese Veranstaltung bietet Investoren und Interessierten die Möglichkeit, Einblicke in die Aktivitäten von Quanterix und die zukünftigen Perspektiven im Bereich wissenschaftlicher Entdeckungen durch Biomarker-Diagnostik zu erhalten.
- None.
- None.
The presentation will be available virtually and participants can register using this link. The presentation will be available following the conference on Quanterix’s website here.
To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix’s Simoa® technology, visit: https://www.quanterix.com/simoa-technology/.
About Quanterix
From discovery to diagnostics, Quanterix’s ultra-sensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806815882/en/
Media:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
Investor Relations:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com
Source: Quanterix Corporation
FAQ
When is Quanterix (QTRX) presenting at the Canaccord Genuity Growth Conference?
Who will be representing Quanterix (QTRX) at the Canaccord Genuity conference?
How can I access Quanterix's (QTRX) presentation at the Canaccord Genuity conference?
What is Quanterix's (QTRX) main focus as a company?
